Vantage logo

Bayer’s gene therapy juggling act

Two arm’s-length acquisitions and two licensing deals have given Bayer a cell and gene therapy unit; now to bring it all together.

Vantage logo

Recycling pays off for Mereo

The company has spent five years buying in discontinued projects, and at last has managed to sell one of these on at a nice profit.

Vantage logo

Finding the next Vertex

Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.